David Aaron Eichenbaum, MD CURRICULUM VITAE

Collaborative Associate Professor, Department of Ophthalmology
July 2019-Present

• Morsani College of Medicine, University of South Florida
Clinical Assistant Professor, Department of Ophthalmology
November 2007-July 2019

• Morsani College of Medicine, University of South Florida

Vitreoretinal Surgery, Tufts/Ophthalmic Consultants of Boston
July 2005 – June 2007

• Tufts New England Eye Center

• Ophthalmic Consultants of Boston

Morsani College of Medicine at the University of South Florida
July 2002 – June 2005

• Chief Resident, July 2004-June 2005

Austin Medical Education Program – Transitional Internship
July 2001 – June 2002

• Brackenridge Hospital – Austin, Texas

University of South Florida College of Medicine
August 1997 – May 2001

• Doctor of Medicine

University of South Florida College of Arts and Sciences
August 1994 – July 1997

• Bachelor of Arts

• Graduated Medical Honors Program

• Graduated University Honors Program

Awards
• Guest of Honor, New England Ophthalmological Society Meeting, 2022

• Alumnus of the Year Recipient, Morsani College of Medicine at the University of South Florida Department of Ophthalmology, 2022

• Fellow, American Society of Retina Specialists, 2021

• American Society of Retina Specialists Honor Award, 2020

• Best Scientific Poster Award (Retina), American Academy of Ophthalmology Annual Meeting, 2015

• Michael R. Redmond, MD Outstanding Young Ophthalmologist Leadership Award from the Florida Society of Ophthalmology, 2015

• David D. Donaldson Clinical Faculty Teaching Award, Morsani College of Medicine at the University of South Florida Department of Ophthalmology, 2015

Appointed Offices
• Medical Board Member, Macular Degeneration Association, 2023-Present

• Retina World Congress Video Gallery Committee, 2022-Present

• President-Elect, Florida Society of Ophthalmology, 2022-2023

• Education Program Co-Chair, Florida Society of Ophthalmology, 2021-Present

• Vice President of Education, Florida Society of Ophthalmology, 2014-2020

• Retina-Vitreous Subspecialty Symposium Chair, Florida Society of Ophthalmology Masters in Ophthalmology Meeting, 2015, 2017-Present

• Regional Representatives Chair, Florida Society of Ophthalmology, 2013-2014

• Industry Council Vice Chair, Florida Society of Ophthalmology, 2012-2013

• President, Tampa Bay Ophthalmic Society 2012-2013

• Vice President, Tampa Bay Ophthalmic Society, 2011-2012

• Treasurer, Tampa Bay Ophthalmic Society, 2010-2011

• Secretary, Tampa Bay Ophthalmic Society, 2009-2010

Residency
• Chief Resident 2004-2005

College of Medicine
• President, Student Council of the USF College of Medicine 2000-2001

• President, USF Chapter of the American Medical Student Association 1998-1999

• American Board of Ophthalmology, Certified 2007, Recertified 2017

• Florida Medical License: ME90466

• St. Anthony’s Hospital, St. Petersburg, Florida

• All Children’s Hospital, St. Petersburg, Florida

• Northside Hospital, St. Petersburg, Florida

• St. Joseph’s Hospital, Tampa, Florida

Peer-Reviewed Articles

Jaffrey C , Eichenbaum DA, Denham D, Norman J. A Novel Pancreatic Model: the Snip Method of Pancreatic Isolation for In Vitro Study. Pancreas, 1999; 19:377-381.

Goldstein B, Eichenbaum DA. A 65 Year-Old Woman with Visual Changes. Digital Journal of Ophthalmology, 2005. Accessed 15 March 2007. <http://www.djo.harvard.edu/site.php?url=/physicians/gr/799>

Eichenbaum DA, Pavan PR. Maculopathy in a Young Person. Digital Journal of Ophthalmology, 2006. Accessed 15 March 2007. <http://www.djo.harvard.edu/site.php?url=/physicians/gr/875>

Baumal C, Eichenbaum DA. Intravitreal Bevacizumab for the Treatment of Subfoveal CNV Secondary to AMD. Retina Today, Summer 2006; 16-18.

Eichenbaum DA, Heier JS. Multiple Repeated Intravitreal Triamcinolone Treatment for Radiation-Induced Macular Edema. Retinal Cases and Brief Reports, Fall 2007; 1(4):202-204.

Eichenbaum DA. The Job Search and Interviewing. Retina Today. January/February 2008; 24-25.

Eichenbaum DA. Navigating Contract Negotiating. Retina Today. March/April 2008; 20-21.

Slonim CB, Raizman MD, Eichenbaum DA, Nichols-Kay C, Joshi S, Gallager P. Uveitis. Ocular Infection and Inflammation, Winter 2009; 1(2): 3-13

Davis A, Cohen SM Pautler SE, Billiris-Findlay K, Eichenbaum DA. Acta Ophthalmologica. Beta Blocker Use and Age-Related Macular Degeneration. June 2011; 118(12):2453-60.

Golen JR, Eichenbaum DA. Retinal Cases and Brief Reports. Neovascularization of the Optic Disk and Vitreous Hemorrhage After Immune Recovery and Treatment of Cytomegalovirus Retinitis in an HIV-Positive Patient. Fall 2013;7(4): 395-298.

Eichenbaum DA, Wolfe JD, Law JC, Shah RJ. Retina Times. Road-Testing the Alcon Ultravit High Speed Vitrectomy Probe. Winter 2013; 31(5): 29-31.

Davis A, Cohen SM, Pautler SE, Billiris-Findlay K, Eichenbaum DA. Correspondence. Retina. 2013 Nov-Dec; 33(10):2185.

Cohen S, Billiris-Findlay K, Eichenbaum D, Pautler S. Ophthalmic Surgery, Lasers, and Imaging Retina. Topical Lidocaine Gel With and Without Subconjunctival Lidocaine Injection for Intravitreal Injection: a Within-Patient Study. June 2014. 45(4):306-10.

Eichenbaum DA. Retina Today. Exploring the DME Treatment Decision Tree. November/December 2014; 52-58.

Patel HS, Eichenbaum DA. Ophthalmic Surgery, Lasers, & Imaging Retina. Geographic Atrophy: clinical impact and emerging treatments. January 2015; 46(1): 8-13.

Eichenbaum DA. Ophthalmic Surgery, Lasers, and Imaging. Letter to the Editor. Comment on Geographic Atrophy: clinical impact and emerging treatments. March 2015; 46(3): 301.

Eichenbaum DA, Kitchens JW, Moshfeghi AA. Retina Today. Switching Therapies in Patients with DME. April 2015; 10(3) 74-76.

Patel HS, Eichenbaum DA. Retina Today. Breakthrough Treatment Modalities for Hereditary Retinal Diseases. April 2016; 1-3.

Eichenbaum DA. Millennial Eye. Lighting in a Bottle: and exploration of the rapid pace of innovation in medical and surgical retina. Cover Focus, May/June 2016.

Salman Y, Eichenbaum DA. New Retina MD. Meeting an Unmet Need: Geographic Atrophy. Cover Focus, Issue 3 2016, 32-34.

Eichenbaum DA, Lowenstein A, Garg SJ, Pieramici DJ. Retina TImes. Retina’s Walking Wounded: Coming Back After an Injury. Summer 2017 35(2); 14-15, 35.

Eichenbaum DA. The Ophthalmologist. Jury’s Out. Placing the HAWK/HARRIER Data in the Wider Context of nAMD anti-VEGF Trial Data. December 2017.

Khanani AM, Eichenbaum D, Schlottman PG, Tuomi L, Sarraf D. Retina. Optimal Management of Pigment Epithelial Detachments in Eyes with Neovascular Age-Related Macular Degeneration. November 2018;38(11): 2103-2117.

Eichenbaum DA, Buzengo C, Weng CY, Dhoot DS, Wykoff CC, Sheth VS. Ophthalmic Surg Lasers Imaging Retina. When and How to Incorporate Steroids for Persistent Diabetic Macular Edema: A Discussion of Real-World Treatment Optimization Strategies. 2018 Jul 1; 49(7):SS-S15.

Wykoff CC, Eichenbaum DA, Roth DB, Hill L, Fung AE, Haskova Z. Ranibizumab Induces Regression of Diabetic Retinopathy in Most Patients at High Risk of Progression to Proliferative Retinopathy. Ophthalmology Retina, 2018;2(10):997-1009.

Eichenbaum D, White Jr. AA. Decision making in diabetic retinopathy treatment. Ret Phys., 2018;15(7) 32-34,44

Eichenbaum DA, Duerr E, Patel HR, Pollack SM. Monthly Versus Treat-and-Extend Ranibizumab for Diabetic Macular Edema: A Prospective, Randomized Trial. Ophthalmic Surg Lasers Imaging Retina. November 2018; 49(11) e191-e197

Schechet SA, Adams OE, Eichenbaum DA, Hariprasad SM. Macular thickness amplitude changes when switching from discontinuous to continuous therapy for diabetic macular oedema. BMJ Open Ophth 2019;4:e000271. doi:10.1136/bmjophth-2019-000271.

Eichenbaum DA. My Switch to New Needles for Intravitreal Injection. Retina Today, October 2019; 2-3.

Khanna S, Komati R, Eichenbaum DA, Hariprasad I, Ciulla T, Hariprasad S. Current and upcoming anti-VEGF therapies and dosing strategies for the treatment of neovascular AMD: a comparative review. BMJ Open Ophthalmology 2019;4e000398. Doi 10/1136/bmjophth-2019-000398

Liebmann JM, Barton K, Weinreb RN, Eichenbaum DA, Gupta PK, McCAb CM, Wolfe JD, Ahmed I, Sheybani A, Craven ER. Evolving Guideline for Intracameral Injection. J Glaucoma. 2020;29 Suppl 1: S1-S7. doi:10.1097/IJG.0000000000001451

Crane AM, Eichenbaum DA. Surgical pearls for the EVA platform. Retina Today. 2020;15(1):28-29.

Eichenbaum DA. Curbing our enthusiasm for telemedicine and deciding on treatments during COVID-19. Retina Today. 2020; 15(4):43-45.

Mansour SE, Kiernan DF, Roth DB, Eichenbaum DE, Holekamp NM, Kaba S, Werts E.Two-year interim safety results of the 0.2ug/day fluocinolone acetonide intravitreal implant for the treatment of diabetic macular oedema: the observational PALADIN study. British Journal of Ophthalmology. Published Online First 27 May 2020. Doi: 10.1136/bjophthalmol-2020-315984

Hussain RM, O’Leary P, Eichenbaum DA, Hariprasad SM. Faricimab: Anti-Ang2/anti-VEGF-A bispecific antibody. Drugs of the Future 2020, 45(7): 449-457 CCC: 0377-8282/2020 DOI: 10.1358/dof.2020.45.7.3127028

Yu HJ, Kiernan DF, Eichenbaum D, Sheth VS, Wykoff CC. Home Monitoring of Age-Related Macular Degeneration: Real-World Utility of the ForeseeHome Device for Detection of Neovascularization [published online ahead of print, 2020 Aug 15]. Ophthal Retina. 2020, S2468-6530(20)30331-6. DOI:10.1016/j.oret.2020.08.003

Barron C, Eichenbaum DA. A review of clinical trial data for DME: BOULEVARD and MEAD. Retina Today. 2020; 15(6) 34-36.

Eichenbaum D. Updates in the management of non-neovascular age-related macular degeneration. Retina 360: Advances in the Management of Retina Diseases. 2020;1(4):7-10.

Eichenbaum DA, Liebmann JM, Barton K, Weinreb RN, Gupta PK, McCabe CM, Wolfe JD, Ahmed I, Sheybani A, Craven ER. Response to Letter to the Editor Evolving Guidelines for Intracameral Injection. J Glaucoma. 2020 Oct 16. doi: 10.1097/IJG.0000000000001707. Epub ahead of print. PMID: 33074961.

Steinle N, Eichenbaum DA, Goodale S, Ratliff AL. The Business of Medical Retina: Overcoming Payor Challenges. Retina Today. October 2020.

Yu HJ, Kiernan DF, Eichenbaum DA, Sheth VS, Wykoff CC, Reply, Ophthalmology Retina, Volume 5, Issue 1, 2021, Pages e1-e2, ISSN 2468-6530, https://doi.org/10.1016/j.oret.2020.09.022.

Enríquez AB, Baumal CR, Crane AM, Witkin AJ, Lally DR, Liang MC, Enrique JR, Eichenbaum DA. Early Experience With Brolucizumab Treatment of Neovascular Age-Related Macular Degeneration. JAMA Ophthalmol. Published online February 25, 2021. doi:10.1001/jamaophthalmol.2020.7085.

Eichenbaum D. Assessing AMD therapies: Changing the interval vs. changing the agent. Retinal Physician 2021;18(3) (Suppl):S10-S12.

Ho A, Heier J, Holekamp N, Garfinkel R, Ladd B, Awh C, Singh R, Sanborn G, Jacobs J, Elman M, Loewenstein A, Eichenbaum D. Real-World Performance of a Self-Operated Home Monitoring System for Early Detection of Neovascular Age-Related Macular Degeneration. J. Clin. Med. 2021, 10, 1355. https://doi.org/10.3390/jcm10071355.

Singer M, Singh R, Gibson A, Moini H, Reed K, Vitti R, Du W, Eichenbaum D, Association of Early Anatomic Response with Visual Function in Neovascular AMD, Ophthalmology, 2021, ISSN 0161-6420, https://doi.org/10.1016/j.ophtha.2021.05.011.

Khanani AM, Russell MW, Aziz AA, Danzig CJ, Weng CY, Eichenbaum DA, Singh RP. Angiopoietins as Potential Targets in Management of Retinal Disease. Clin Ophthalmol. 2021;15:3747-3755, https://doi.org/10.2147/OPTH.S231801.

Wykoff CC, Hershberger V, Eichenbaum D, Henry E, Younis HS, Chandra P, Yuan N, Solloway M, DePaoli A. Inhibition of Complement Factor 3 in Geographic Atrophy with NGM621: Phase 1 Dose-Escalation Study Results. Am J Ophthalmol. 2022 Mar;235:131-142. doi: 10.1016/j.ajo.2021.08.018. Epub 2021 Sep 10. PMID: 34509438.

Eichenbaum D. Management of chronic postoperative CME with uveitis. Modern Retina. 2021 Oct:34-36.

Baumal C, Eichenbaum D, Chen X. Ranibizumab and Neovascular Age-related Macular Degeneration. touchREVIEWS in Ophthalmology. 2021;15(2): 55-57.

Wykoff C, Abreu F, Adamis A, Basu K, Eichenbaum D, Haskova Z, et al. Efficacy, Durability, and Safety of Intravitreal Faricimab with Extended Dosing up to Every 16 Weeks in Patients with Diabetic Macular Oedema (YOSEMITE and RHINE): Two Randomised, Double-Masked, Phase 3 Trials. The Lancet, 2022, ISSN 0140-6736,https://doi.org/10.1016/S0140-6736(22)00018-6.

Eichenbaum DA, Ahmed A, Hiya F. Ranibizumab port delivery system: a clinical perspective BMJ Open Ophthalmology 2022;7:e001104. doi: 10.1136/bmjophth-2022-001104

Wang R, McClard CK, Laswell S, Mahmoudzadeh R, Salabati M, Ammar M, Vannavong J, Aziz A, Ewald A, Calvanese A, Lehman E, Fried S, Windham V, Strutt A, Saroj N, Khanani A, Eichenbaum D, Regillo C, Wykoff C. Quantifying burden of intravitreal injections: questionnaire assessment of life impact of treatment by intravitreal injections (QUALITII). BMJ Open Ophthalmology 2022;7:e001188. doi: 10.1136/bmjophth-2022-001188

Eichenbaum DA, Ahmed A, Hiya FRanibizumab port delivery system: a clinical perspective BMJ Open Ophthalmology 2022;7:e001104. doi: 10.1136/bmjophth-2022-001104

Patel SS, Lally D, Hsu J, Wykoff CW, Eichenbaum DA, Heier JS, Jaffe GJ, Westby K, Desai D, Zhu L, Khanani A. Avacincaptad pegol for geographic atrophy secondary to age-related macular degeneration: 18-month findings from the GATHER1 trial. Eye (2023). https://doi.org/10.1038/s41433-023-02497-w

Kolomeyer AM, Eichenbaum DA, Kiernan SF, Suner IJ, Hariprasad SM. The 0.19-mg Fluocinlone Acetodine Implant for the Treatment of Diabetic Macular Edema: an Expert Consensus. Ophthalmic Surgery, Lasers and Imaging Retina, 2023;54(3):166–173. Published Online: March 01, 2023 https://doi.org/10.3928/23258160-20230215-01

Eichenbaum D, Brown D, Ip M, Khanani A, Figueroa M, McAllister I, Laude A, Guruprasad B, Tang S, Gmeiner B, Clemens A, Souied E. Impact of Retina Fluid-Free Months on OUtcomes in Neovascular Age-Related Macular Degeneration: a Treatment-Agnostic Analysis of the HAWK and HARRIER Studies. Retina 43(4):p 632-640, April 2023. | DOI: 10.1097/IAE.0000000000003699

Ahmed AA, Hiya FE, Eichenbaum DA. Bilateral Hypotony Maculopathy Associated With Ipilimumab and Nivolumab Therapy Unresponsive to Corticosteroid Treatment. Ophthalmic Surg Lasers Imaging Retina, 2023;54(5):301-304. doi: 10.3928/23258160-20230405-01. PMID: 37078857.

Boyer DS, Gonzalez VH, Eichenbaum DA. Supplement to Retina Today. DRCR.net Protocol T: A comparative effectiveness of intravitreal aflibercept, bevacizumab, and ranibizumab for diabetic macular edema. March 2014.

Eichenbaum D, Albini T, Fortun JA, Kitchens JW, Reichel E. Supplement to Retina Today. Current Insights Into the Management of Diabetic Macular Edema. April 2014.

Pieramici D, Blaha G, Eichenbaum D, Singh R. Supplement to Retina Today. An Update on the Latest Clinical Trials on DME: Are They Applicable to Other Disease States? November/December 2015.

Eichenbaum, D. Insert to Retina Today. AMD Disease Resource Education Center. September 2016, 46-49.

Wykoff C, Baumal C, Eichenbaum D, Shah C. Supplement to Retina Today. DME in 2016: A Review of Treatment Guidelines and the Role of Early Appropriate Therapy September 2016.

Wykoff C, Baumal C, Eichenbaum D, Shah C. Supplement to New Retina MD. A Review of Treatment Guidelines and the Role of Early Appropriate Therapy August 2017/Issue 2.

Holekamp NM, Eichenbaum D, Khanani AM, Singer M. The latest in clinical trials and best practices. Retina. 2020 (July suppl): 1-12.

Eichenbaum DA, Boyer D, Rachitskaya A, Regillo C, Vajzovic L. Treating Retinal Disorders: Moving Beyond anti-VEGF. Retina Today. Bryn Mawr, PA: Evolve Medical Education/Bryn Mawr Publications; 2021. p.1-16.

Groden L, Dorsett K., Eichenbaum D. Pachymetry “Studies in LASIK.” Castroviejo Cornea Society, 26th Annual Meeting, October 21, 2000
Eichenbaum D, Cohen S, Billiris-Findlay, K. “Monthly Versus Treat-and-Extend Ranibizumab for Center-Involving Diabetic Macular Edema: a Prospective Randomized Investigator-Sponsored Trial,” Club Vit, July 1, 2014

Eichenbaum D, Cohen S, Billiris-Findlay, K. “Monthly Versus Treat-and-Extend Ranibizumab for Center-Involving Diabetic Macular Edema: a Prospective Randomized Investigator-Sponsored Trial,” American Society of Retinal Specialists (ASRS), August 11, 2014

Eichenbaum D, Hill L, Tuomi L, “How Do Large Pigment Epithelial Detachments Respond to Ranibizumab Treatment in Wet AMD Patients?” Masters in Ophthalmology Annual Meeting of the Florida Society of Ophthalmology, June 27, 2015

Eichenbaum D, Hill L, Tuomi L, “How Do Large Pigment Epithelial Detachments Respond to Ranibizumab Treatment in Wet AMD Patients?” American Society of Retina Specialists (ASRS), July 13, 2015

Eichenbaum D, Reichel E, Csaky K, Harper T, Dhoot D, “Medical Retina Clinic: From Common to Obscure. What Would You Do?” Vit Buckle Society Meeting, March 18, 2016

Eichenbaum D, Hill L, Lu N, Gune S, Tuomi L, “Response to Ranibizumab in Eyes with Pigment Epithelial Detachments, Including Eyes that Developed RPE Tears: Data from the HARBOR Study,” American Society of Retina Specialists (ASRS), August 10, 2016

Eichenbaum D, “The Role of the Retina Specialist,” Millennial Eye Live, October 29, 2016

Eichenbaum D, Wykoff C, Baumal C, Khurana R, “Medical Retina Panel: Just Another Day,” Vit Buckle Society Meeting, April 7, 2017

Eichenbaum D, “Retinal Vein Occlusion: Big Picture Takeaways,” Masters in Ophthalmology Annual Meeting of the Florida Society of Ophthalmology, June 3, 2017

Eichenbaum D, Duker J. Introduction for “VBS Lifetime Mentorship Lecture: A Reappraisal of Macular Hole Classification,” Vit Buckle Society Meeting, March 24, 2018

Eichenbaum D, Rogers D, Tan J, Moderators, “Endophthalmitis: Minimizing Risk and Optimizing Outcomes,” Vit Buckle Society March 24, 2018

Eichenbaum D, “Real-World Results of Long-Acting Intravitreal Fluocinolone Injection,” Masters in Ophthalmology Annual Meeting of the Florida Society of Ophthalmology, June 9, 2018

Eichenbaum D, Day B, Tuomi L. “Percentage of Patients Maintained on Quarterly Anti-VEGF Dosing for the Treatment of Neovascular Age-Related Macular Degeneration Across Key Clinical Trials,” American Society of Retinal Specialists (ASRS), July 21, 2018

Eichenbaum D, Sahni J, Sadikhov S, Pauly-Evers M, Szczesny P, Weikert R. “Anti-VEGF/Anti-Angiopoietin-2 Bispecific Antibody Faricimab in Diabetic Macular Edema: Key Secondary and Exploratory Outcomes in the Phase 2 BOULEVARD Clinical Trial,” EURETINA, September 21, 2018

Eichenbaum D, “Association Between Early Vision-Related Quality of Life Outcomes and Anatomic Dryness Response in Neovascular Age-Related Macular Degeneration (nAMD),” Retina World Congress, March 22, 2019

Eichenbaum D, “Starting a Clinical Trial Program,” American Society of Retina Specialists Business of Retina, March 30, 2019

Eichenbaum D, “Novel Retina Products in Late Phase Development,” Masters in Ophthalmology Annual Meeting of the Florida Society of Ophthalmology, June 29, 2019

Eichenbaum D, Blotner S, Singh N, Barteselli G, Gune S, “Ladder Phase 2 Trial of the Port Delivery System with Ranibizumab: End of Study Results,” American Society of Retina Specialists (ASRS), July 25, 2020

Eichenbaum D, Barteselli G, Blotner S, Gune S. “Key Learnings from the Phase 2 LADDER Trial of the Port Delivery System with Ranibizumab for Neovascular AMD,” Retina Society, September 8, 2020.

Wyoff C, Hershberger V, Eichenbaum D, Yunis, H, Henry E, Chandra P, DePaoli A, “Inhibition of Complement C3 in Geographic Atrophy with NGM621: Phase 1 Dose-Escalation Study Results,” American Academy of Ophthalmology, November 2020

Baumal C, Eichenbaum D. “Early Experience with Brolocizumab for Neovascular Age-Related Macular Degeneration,” Macula Society, February 6, 2021

Eichenbaum D, “Advanced Research Department Management,” American Society of Retina Specialists Business of Retina, March 6, 2021

Eichenbaum D, Wykoff C, Hershberger V, Henry E, Younis H, Chandra P, Le N, Yuan N, DePaoli A. “Inhibition of complement C3 in geographic atrophy with NGM621: Phase 1 study results,” Association for Research in Vision and Ophthalmology, May 7, 2021

Aziz A, Khanani A, London N, Hagen M, Danzig C, Kulkarni A, Sheth V, Jhaveri C, Eichenbaum D, Singer M. “Real World Efficacy and Safety of Brolucizumab in Neovascular AMD: the REBEL Study,” Association for Research in Vision and Ophthalmology, May 7, 2021

Eichenbaum D, Singh N, Kaufman D, Kardatzke D, Patel S, Gune S, Chidambaram J, Barteselli G. “Primary Analysis of the Phase 3 Archway Trial of the P0rt Delivery System with Ranibizumab (PDS) in Neovascular AMD,” Oxford Ophthalmology Congress, July 6, 2021.

Eichenbaum D. “Port Delivery System Surgery Story,” Masters in Ophthalmology Annual Meeting of the Florida Society of Ophthalmology, July 10, 2021.

Eichenbaum D. “OPT-302: a VEGF C/D ‘Trap’ Inhibitor for Retinal Eye Diseases,” Stanford Retina Innovation Summit July 17, 2021.

Figueroa M, Eichenbaum D, Brown D, Khanani A, McAllister I, Laude A, Prasad G, Tang S, Gmeiner B, Clemens A, Souied E. “Maximum Consecutive Fluid-Free Months and its Association with Visual and Anatomical Outcomes in nAMD: A Post-Hoc Analysis of the 96-week Data from HAWK and HARRIER,” EURETINA Virtual Meeting September 9-12, 2021.

Eichenbaum D, Heier J, Dhoot D, Sheth V, Danzig C, Singer M, London N. “Establishing a Successful Clinical Research Department: The Real Deal,” Clinical Trials at the Summit, Virtual, August 28, 2021.

Eichenbaum D, Wykoff C, Hoskova Z, Lin H, Silverman D, Ives J, Abreu F, Basu K, Tadayoni R. “Efficacy, Safety, and Durability of Faricimab in Diabetic Macular Edema: One-Year Results from the Phase 3 YOSEMITE and RHINE Trials,” Retina Society, October 2, 2021.

Eichenbaum D, Brown D, Khanani A, Figueroa M, McAllister I, Laude A, Prasad G, Tang S, Gmeiner B, Clemens A, Souied E. “Maximum Consecutive Fluid-Free Months and its Association with Visual and Anatomical Outcomes in nAMD: a Post-Hoc Analysis of the 96-week Data from HAWK and HARRIER,” ASRS Annual Meeting, October 11, 2021.

Eichenbaum D, Singh N, Barteselli G, Menezes A, Malhotra V. “Key Surgical Pearls of the Implant Insertion Procedure,” 75th Annual Congress of Japan Clinical Ophthalmology, October 29, 2021.

Boyer, D, Eichenbaum D, Sunil P, Barakat M. “Interim Results of a Phase 1, Prospective, Open-label, Dose-escalation Study of EYP-1901 in Wet Age-related Macular Degeneration,” AAO Retina Sub-Specialty Day, November 12, 2021.

Eichenbaum D, Brown D, Ip M, Khanani A, Figueroa M, McAllister I, Laude A, Guruprasad B, Tang S, Gmeiner B, Clemens A, Souied E. “A Treatment-Agnostic Analysis Of the Long-Term Impact of IRF and SRF On Vision and Anatomy In nAMD In the HAWK And HARRIER Studies,” AAO Retina Sub-Specialty Day, November 12, 2021.

Eichenbaum D, Kim J. “Should All Fluids Be Eliminated in the Management of Neovascuular AMD?” 9th International Congress on OCT and OCT Angiography in Rome (ICOOR), December 17, 2021.

Eichenbaum D. Long-Term (+3 Year) Safety and Efficacy Data for the Port Delivey System: Interim Analysis Results of the Portal Extension Study of the POrt Delivery System with Ranibizumab (PDS) in Patients with Neovascular Macular Degeneration (nAMD). Angiogenesis, Exudation, and Degeneration 2022, February 12, 2022.

Ip M, Eichenbaum D, Brown D, Khanani A, Figueroa M, McAllister I, Laude A, Guruprasad B, Tang S, Gmeiner B, Clemens A, Souied E. “A Treatment-Agnostic Analysis Of the Long-Term Impact of IRF and SRF On Vision and Anatomy In nAMD In the HAWK And HARRIER Studies,” Angiogenesis, Exudation, and Degeneration 2022, February 12, 2022.

Lim J, Wells J, Eichenbaum D, Danzig C, Asik K, Haskova Z, Mohan S, Silverman D, Tang Y, Lin H. “Efficacy, Durability, and Safety of Faricimab in Diabetic Macular Edema: 2-Year Results from the Phase 3 YOSEMITE and RHINE Trials,” Association for Vision and Research in Ophthalmology, May 1-4, 2022.

Lim J, Wells J, Eichenbaum D, Danzig C, Asik K, Haskova Z, Mohan S, Silverman D, Tang Y, Lin H. “2-Year Results from the Phase 3 YOSEMITE and RHINE Trials: Efficacy, Durability, and Safety of Faricimab in Diabetic Macular Edema,” American Ophthalmological Society, May 20, 2022.

Singh R, Wells J, Baumal C, Danzig C, Eichenbaum D, Lim J, Lin H, Mohan S, Silverman D, Tang Y, Haskova Z. “Efficacy, Durability, and Safety of Faricimab in Diabetic Macular Edema: 2-Year Results from the Phase 3 YOSEMITE and RHINE Trials,” Retina World Congress, May 12-15, 2022.

Eichenbaum D, Baumal C, Chakravarthy U, Kitchens J, Jaffe G, Gerendas B, Abreu F, Camino A, Jain N, Tang Y, Haskova Z. “Personalized Treatment Interval (PTI) Dosing Dynamics Over 2 Years in the Phase 3 YOSEMITE and RHINE Trials of Faricimab in Diabetic Macular Edema,” Retina World Congress, May 12-15 2022.

Eichenbaum D, Basu K, Ives J, Lin H, Quezada C, Silverman D, Kotecha A, Willis J. “Faricimab in Neovascular Age-Related Macular Degeneration: Updated Safety, Efficacy, and Durability in the Phase 3 TENAYA and LUCERNE Trials,” Royal College of Ophthalmologists Annual Congress, May 23-26, 2022.

Eichenbaum D, Lin H, Mohan S, Silverman D, Tang Y, Haskova Z. “Efficacy, Durability, and Safety of Faricimab in Diabetic Macular Oedema: 2-Year Results from the Phase 3 YOSEMITE and RHINE Trials,” Royal College of Ophthalmologists Annual Congress, May 23-26, 2022.

Danzig C, Wells J, Eichenbaum D, Lim J, Asik K, Haskova Z, Mohan S, Silverman D, Tang Y, Lin H. “Efficacy, Durability, and Safety of Faricimab in Diabetic Macular Edema: 2-Year Results from the Phase 3 YOSEMITE and RHINE Trials,” American Diabetes Association 82nd Scientific Sessions, June 3-7, 2022.

Eichenbaum D, Wells J, Lim J, Danzig C, Asik K, Haskova Z, Mohan S, Silverman D, Tang Y, Lin H. “Efficacy, Durability, and Safety of Faricimab in Diabetic Macular Edema: 2-Year Results from the Phase 3 YOSEMITE and RHINE Trials,” American Society of Retina Specialists (ASRS) 2022, July 13-16, 2022.

Merrill P, Eichenbaum D. “Three Year Outcomes from the PALADIN Phase IV Study: A Deep Dive intoEyes Requiring IOP Lowering Surgery,” American Society of Retina Specialists (ASRS) 2022, July 13-16, 2022.

Singh R, Barakat M, Ip M, Higgins P, Sheth V, Eichenbaum D, Wykoff C, Kim Y, He F, Cho G, Wang Y, Emmanuelli A. “Brolucizumab for the Treatment of Diabetic Macular Edema: 52-Week Results from the KINGFISHER Study,” American Society of Retina Specialists (ASRS) 2022, July 13-16, 2022.

Lally D, Heier J, Sadda S, Eichenbaum D, Danzig C. “Progression of Atrophy in AMD: Post-Hoc Analysis from the GATHER1 Study,” American Society of Retina Specialists (ASRS) 2022, July 13-16, 2022.

Dang S, Nielsen J, Lalwani G, Moinfar N, Parke W, London N, Kimua A, Maher D, Jumper M, Lord K, Pieramici D, Sheth V, Eichenbaum D, Danzig C, Harkey S, Defenbaugh K, Goodale S, Sodhi G, Diamond R, White M, Wykoff C. “Anti-VEGF Injection Prior Authorization Impacts on Retina Practices,” American Society of Retina Specialists (ASRS) 2022, July 13-16, 2022.

Eichenbaum D, Feistmann J, Qureshi J, Sanders R. “Disruptive/Transformative Technology and Trends in the Retina Sphere,” American Society of Retina Specialists (ASRS) 2022, July 13-16, 2022.

Barakat M, Singh R, Ip M, Higgins P, Sheth V, Eichenbaum D, Wykoff C, Kim Y, He F, Cho G, Wang Y, Emanuelli A. “Brolucizumab for the Treatment of Diabetic Macular Edema: 52-week results from the KINGFISHER Study,” EURetina, September 1-4, 2022.

Emanuelli A, Barakat M, Singh R, Ip M, Higgins P, Sheth V, Eichenbaum D, Wykoff C, Kim Y, He F, Cho G, Wang Y. “Brolucizumab for the Treatment of Diabetic Macular Edema: 52-week results from the KINGFISHER Study,” World Ophthalmology Congress, September 9-12, 2022.

Eter N, Eichenbaum D, Callaway N, Morral M, Smith R, Compaciaro C. “Long-Term Safety and Efficacy of the Port Delivery System with Ranibizumab (PDS) in Neovascular Age-Related Macular Degeneration: Interim Analysis of the Portal Extension Trial,” EURetina, September 1-4, 2022.

Baumal C, Wells J, Danzig C, Eichenbaum D, Lim J, Sclottmann P, Singh R, Lin H, Mohan S, Asik K, Silverman D, Tang Y, Haskova Z. “Efficacy, Durability, and Safety of Faricimab in Diabetic Macular Edema: 2-Year Results from the Phase 3 YOSEMITE and RHINE Trials,” American Academy of Ophthalmology, September 30-October 3, 2022.

Eichenbaum D, Klufas M, Garg S, Hahn P, Sadda S, Choudhry N, Waheed N, Kim J, Schneider E, Sebag J, Cohen M. “The Retina Debates Continue: 2022, Gene Therapy in Neovascular AMD/Diabetic Macular Edema vs Regional Depot,” American Academy of Ophthalmology, September 30-October 3, 2022.

Kaiser P, Khanani A, Eichenbaum D, Wykoff C, Hsu J, Mones J, Nielsen J, Holz F, Tufail A, Jaffe G, D’Amico D, Sheth V, Zhu L, Clark J, Patel H, Heier J. “Safety of Intravitreal Avacincaptad Pegol in Geographic Atrophy: GATHER1 and GATHER2 Results,” Retina Society, November 2-5, 2022.

Eichenbaum D. “Surgical Delivery Strategies and Gene Therapy for Atrophic AMD: Preliminary Results from a First-In-Human Phase I/II Gene Therapy Trial (FOCUS) of GT005 Using the Orbit Subretinal System,” Retina Society, November 2-5, 2022.

Eichenbaum D. “Real-World Experience with the Port Delivery System,” OSN New York Retina, November 11-13, 2022.

Eichenbaum D, “GATHER1/GATHER2: Comparison of Trial Design and Baseline Patient Populations Influencing Lesion Growth,” Angiogenesis, Exudation, and Degeneration 2023, February 10-11, 2023.

Baumal C, Lally D, Patel S, Boyer D, Barakat M, Eichenbaum D. “The DAVIO Trial: A Phase I, Open-Label, Dose-Escalation Study of EYP-1901 (Vorolanib) demonstrating reduced Wet Age-Related Macular Degeneration Treatment Burden with Sustained Tyrosine Kinase Inhibitor Therapy,” Macula Society, February 15-18, 2023.

Khanani A, Hershberger V, Kay C, Hu A, Eichenbaum D, Jaffe G, Chung C, Honarmand S, Nien C, Lee S, Kabra H, Kirn D, Kim R. “PRISM: a Phase 1/2 Clinical Trial Evaluating 4D-150, a Dual-transgene Intravitreal Gene Therapy in Patients with Age-Related Macular Degeneration: Interim Results,” Association for Research in Vision and Ophthalmology, April 23-27, 2023.

Eichenbaum DA, Slonim CB. “Disorders of the eye”. Eds. Cuppett M, Walsh KM. General Medical Conditions in the Athlete. St. Louis: Mosby Inc, 2005. 217-242. Print.

Henderson BA, Steinert RF, Eichenbaum DA, Heier JS. “Complications of IOL Surgery.” Eds. Albert D, Miller J, Azar D, Blodi B. Albert & Jakobiec’s Principles & Practice of Ophthalmology. Amsterdam: Elsevier, 2007. Sect 9 Ch 121 pg 1-37. Print.

Eichenbaum D, Reichel E. “Optical Coherence Tomography in the Evaluation and Management of Age-Related Macular Degeneration.” In: Age-Related Macular Degeneration (2nd Edition). Italy: Informa Healthcare, 2007. 177-185. Print.

Eichenbaum DA, Park RI, Topping TM. “Postoperative Endophthalmitis.” Ed. Steinert R Cataract Surgery. Amsterdam: Elsevier, 2009. Part VII Ch 55 pg 671-679. Print.

Small L, Eichenbaum DA, Slonim CB. “Disorders of the Eye.” Eds. Cuppett M, Walsh KM, General Medical Conditions in the Athlete (2nd edition). St. Louis: Elsevier Mosby; 2012. Print.

Eichenbaum D. “Future Therapies: New Agents in Preclinical or Pipeline.” Current Management of Diabetic Retinopathy (1st Edition). Eds. Caroline Baumal, Jay Duker. St. Louis: Elsevier, 2018. 123-132, Print.

Eichenbaum D, Goldman D, Wykoff C, Baumal C. “Clinical Scenarios.” Current Management of Diabetic Retinopathy (1st Edition). Eds. Caroline Baumal, Jay Duker. St. Louis: Elsevier, 2018. 133-143, Print.

Eichenbaum D, Groden L. “Lasik Surgery Noncandidates.” Poster. San Diego: American Society of Cataract and Refractive Surgeons, 2004.

Eichenbaum D, Rogers A, Reichel E, Baumal C, Duker J. “Intraocular Bevacizumab (Avastin) for the Treatment for Choroidal Neovascularization and Retinal Vasculopathies.” Poster. Ft. Lauderdale: Association for Vision and Research in Ophthalmology, 2006.

Eichenbaum D, Nguyen J, Heier J. “Ranibizumab in Patients With Choroidal Neovascularization Secondary to Causes Other Than Age-Related Macular Degeneration: A Phase I Study.” Poster. Ft. Lauderdale: Association for Vision and Research in Ophthalmology, 2007.

Nguyen J, Eichenbaum D, Heier J. “Ranibizumab Treatment of Patients With Neovascular AMD Previously Treated With Intravitreal Bevacizumab.” Poster. Ft. Lauderdale: Association for Research in Vision and Ophthalmology, 2007.

Wiegand T, Rogers A, Yates P, Eichenbaum D, Reichel E, Duker J. “Intravitreal Injection of Bevacizumab (Avastin) for Choroidal Neovascularization Caused by Angioid Streaks.” Poster. Ft. Lauderdale: Association for Research in Vision and Ophthalmology, 2007.

Eichenbaum D, Cohen S, Pautler S, Billiris-Findlay K. “A Prospective Study of Ranibizumab for DME: Monthly injections vs Treat-and-Extend.” Poster. Toronto: American Society of Retinal Specialists, 2013.

Eichenbaum D, Hill L, Tuomi L, Fung A. “Is There an Association Between Macular Atrophy Development and Pigment Epithelial Detachment in HARBOR?” Poster PO208. Las Vegas: American Academy of Ophthalmology 2015 Annual Meeting.

Pautler SE, Cohen SM, Findlay KB, Eichenbaum DA, Lopez M. “Clinical Findings of the Posterior Uveal Effusion Syndrome.” Poster PO476. Las Vegas: American Academy of Ophthalmology. 2015 Annual Meeting.

Eichenbaum D, Quezada-Ruiz C, Hill L, Ghanekar A, Haskova Z. “Regression of Diabetic Retinopathy With Ranibizumab in Patients With Diabetic Macular Edema and Highest-Risk Nonproliferative Diabetic Retinopathy” Poster PO236. Chicago: American Academy of Ophthalmology 2016 Annual Meeting.

Eichenbaum D. “Fluocinolone Acetonide (FAc) 0.19mg: Pharmacokinetics and Clinical Relevance” Poster B0343. Baltimore: Association for Research in Vision and Ophthalmology 2017.

Liu M, Eichenbaum D, Taylor S, Wang P, Quezada-Ruiz C. “Branch and Central Retinal Vein Occlusion: Clinical Pearls from Trials of Ranibizumab” Poster B0497. Baltimore: Association for Research in Vision and Ophthalmology 2017.

Eichenbaum D, Wang P, Quezada-Ruiz C. “Branch and Central Retinal Vein Occlusion With and Without Ischemia: Key Clinical Insights From 5 Large Ranibizumab Clinical Trials” Poster 428. Boston: American Society of Retina Specialists 2017.

Eichenbaum D, Day B, Tuomi L. “Quarterly Anti-VEGF Dosing for the Treatment of Neovascular Age-Related Macular Degeneration: a Cross-Trial Comparison” Poster A0156. Honolulu: Association for Research in Vision and Ophthalmology 2018.

Eichenbaum D. “Anatomical Assessment of Fluocinolone Acetonide (FAc) for Diabetic Macular Edema (DME) in PALADIN” Poster PO523. Chicago: American Academy of Ophthalmology 2018.

Eichenbaum D. “Suprachoroidal CLS-TA Improves Visual Acuity and Macular Edema in Noninfectious Uveitis: Results of the Phase 3 PEACHTREE Study & the MAGNOLIA Extension Study” Poster on Demand. Ft. Lauderdale: Retina World Congress 2019.

Eichenbaum D. “Association Between Vision-Related Quality of Life Outcomes and Anatomic Dryness Response in Neovascular Age-Related Macular Degeneration (nAMD): A Post-Hoc Analysis of VIEW Trials” Poster A0270. Vancouver: Association for Research in Vision and Ophthalmology 2019.

Eichenbaum D, Bann-Mo D, Bhakta A, Stoilov I. “It’s the Patient Not the Agent: An Assessment of Anti-VEGF Extended Dosing Intervals in Patients with Wet nAMD.” Poster on Demand. Chicago: American Society of Retina Specialists 2019.

Eichenbaum D, Hugh L, Basu K, Silverman D, Quezada Ruiz C, Haskova Z. “Additional Anatomic Endpoints Support Sustained Outcomes with Faricimab Q16W Flex and Q12W in the STAIRWAY Phase 2 Trial for nAMD.” ePoster PO450. San Francisco: American Academy of Ophthalmology 2019.

London N, Khanani A, Thompson M, Danzig C, Kulkarni A, Sheth V, Jhaveri C, Eichenbaum D, Singer M. “Treating Neovascular AMD Patients with Brolucizumab: a Real-World Study.” ePoster. Virtual Meeting: American Society of Retina Specialists 2020.

Eichenbaum D. “Faricimab: Evidence for Differentiation with Dual Angiopoietin-2 (Ang2)/VEGF-A Inhibition in DME and nAMD.” ePoster PO388. Virtual Meeting: American Academy of Ophthalmology 2020.

Eichenbaum D, Singh N, Kaufman D, Kardatzke D, Patel S, Gune S, Chidambaram J, Barteselli G. “Primary Analysis of the Phase 3 Trial of the Port Delivery System with Ranibizumab (PDS) in Neovascular AMD.” ePoster rco2021.097026e (ePoster P150). Virtual Meeting: Royal College of Ophthalmology 2021.

Eichenbaum D, Singh N, Barteselli G, Menezes A, Malhotra V. “Key Surgical Pearls of the Implant Insertion Procedure for the Port Delivery System with Ranibizumab (PDS).” ePoster. Virtual Meeting: Oxford Ophthalmology Congress 2021.

Wang R, McClard CK, Laswell S, Mahmoudzadeh R, Salabati M, Ammar MJ, Vannavong J, Aziz A, Ewald A, Calvanese AV, Fried S, Windham V, Strutt AM, Saroj N, Eichenbaum DA, Khanani AM, Regillo C, Wykoff CC. Results of a Multicenter Survey to Measure Treatment Burden: Questionnaire to Assess Life Impact of Treatment by Intravitreal Injections (QUALITII). American Society of Retina Specialists (ASRS) 2021. San Antonio TX, October 8-12, 2021.

Danzig CJ, Khanani AM, Eichenbaum DA, Wykoff CC, Hsu J, Lally DR, Sheth V, Heier JS, Patel SS, Nielsen JS. Avacincaptad Pegol, A Novel C5 Inhibitor, Demonstrates a Continued Reduction in the Mean Rate of Geographic Atrophy Growth: 18-Month Results from the Gather1 Clinical Trial. ePoster. American Academy of Ophthalmology, New Orleans, LA November 12-13, 2021.

Want R, McClark CK, Laswell S, Lehman E, Saroj N, Eichenbaum DA, Khanani AM, Regillo C, Wykoff CC, Bowie EM. Gender, Race, and Insurance Status affect Perceived Treatment Burden in Patients Receiving Repeated Intravitreal Injections: findings from the QUALITII Study. American Society of Retina Specialists (ASRS) 2022, July 13-16, 2022. Poster Presentation.

Khan H, Ewing T, Masud M, Sulahria H, Khan M, Sheth V, Graff J, Eichenbaum D, Khanani A. “Real-World Efficacy and Safety of the Ranibizumab Port-Delivery System in Neovascular AMD: The SUMMIT Study,” American Society of Retina Specialists (ASRS) 2022, July 13-16, 2022. Poster Presentation.

Goldberg R, Jaffe G, Gerendas B, Baumal C, Chakravarthy U, Eichenbaum D, Kitchens J, Korobelnik J, Abreu F, Jain N, Tang Y, Camino A, Haskova Z. “Treat-and-Extend Personalized Treatment Interval (PTI) Dynamics in the YOSEMITE/RHINE Trials of Faricimab in DME,” American Academy of Ophthalmology, September 30-October 3, 2022. Poster Presentation.

Khanani A, Wykoff C, Xavier S, Bagheri N, Eichenbaum D, Steinle N, Moshfeghi A, Gurses-Ozden R, Goldstein M. “Interim 28 Weeks Data from an Phase 1 US Study of Sustained Release Axitinib Hydrogel Implant (OTX-TKI) in Previously-Treated Wet AMD Subjects,” American Academy of Ophthalmology, September 30-October 3, 2022. Poster Presentation.

Lally D, Singh R, Barakat M, Hershberger V, Bridges W, Eichenbaum D, Patel S, Roy M, Duker J, Paggiarino D. “EYP-1901: an Open Label, Dose Escalation Study Demonstrating Reduced Wet AMD Treatment Burden with Sustained TKI Inhibition,” American Academy of Ophthalmology, September 30-October 3, 2022. Poster Presentation.

Eichenbaum D, Frese M, Guerriero J, Longo N, Welch L. “Title: Effect of Continuing Education on Guideline-Based Treatment of Patients with Retinal Diseases: A VISION RELIEF Study,” Poster C0476. New Orleans: Association for Research and Vision in Ophthalmology, April 23-27, 2023. Poster Presentation.

Lead Faculty for Market Access Challenges in Retinal Disease, Evolve Medical Education, Ongoing Series 2018-2019, with Ankoor Shah, MD and Rotating Faculty Early Treatment of Diabetic Retinopathy: What the Data Says & How We Communicate it to Our Patient, with Rishi Singh, MD and Judy Kim, MD, 2019

Then, Now, and Tomorrow: Evolving the Role of the Primary Eyecare Provider in the Management of Diabetic Retinopathy, Tampa, Florida December 11th, 2019

Editorial Board, Retina 360: Advances in the Management of Retinal Diseases, Volume 1, 2020
Guest Editor: Switching Anti-VEGF Agents for AMD Treatment: Assessing Therapies and Patient Outcomes, Supplement to Retinal Physician 2021;18(3)

Curbside Consults on Retinal Vein Occlusion Management: Deciphering New Data on RVO Treatment – How Do They Affect Real World Practice? Vindico MedEd Talks hosted by Carl Regillo, MD, June 9th, 2021
Curbside Consults on Retinal Vein Occlusion Management: Use of Imaging in the Diagnosis of RVO, Vindico MedEd Talks hosted by Carl Regillo, MD, June 9th, 2021

The Rise of New Regimens in nAMD and DME Management moderated by Caroline Baumal, MD, FASRS, presented at OSN Retina New York, November 11th, 2022

Investigator Initiated Study of the Effect of Monthly Ranibizumab versus Treat and Extend Ranibizumab for Diabetic Macular Edema. Site Principal Investigator 2012-2016.

Topical lidocaine gel with and without subconjunctival lidocaine injection for intravitreal injection. Site Sub-Investigator 2012-2013.

The University of Virginia TOGA-01: Treatment with Oracea for Geographic Atrophy: Phase 2/3 Study Evaluating the Safety and Efficacy of daily oral administration of doxycycline (ORACEA) vs placebo in subjects with GA. Site Principal Investigator 2014-Present.

Ophthotech Protocol OPH1004A SOLARIS: A Phase 3 Randomized, Double-Masked, Controlled Trial to Establish the Safety and Efficacy of Intravitreous Administration of Fovista (Anti PDGF-B Pegylated Aptamer) Administered in Combination with Either Avastin or Eylea Monotherapy in Subjects with Neovascular Age-Related Macular Degeneration. Site Principal Investigator 2014-2017.

Thrombogenics Protocol TG-MV-018 ORBIT: Ocriplasmin Research to Better Inform Treatment A Phase 4 Trial Evaluating the Clinical Outcomes and Safety in Patients Receiving Jetrea for the Treatment of Symptomatic Vitreomacular Adhesion. Site Principal Investigator 2014-2016.

Thrombogenics Protocol TG-MV-022 OZONE: A Retrospective Review of Patients Treated with Ocriplasmin for Symptomatic VMA Retrospective Observational Trial. Site Principal Investigator 2015-2016.
Genentech-Roche Protocol GX29185 SPECTRI: A Phase 3, Multicenter, Randomized, Double-Masked, Sham-Controlled Study to Assess the Efficacy and Safety of Lampalizumab Administered Intravitreally to Patients with Geographic Atrophy Secondary to Age-Related Macular Degeneration. Site Principal Investigator 2015-2018.

River Vision DME 01RV Phase 1, Open-Label Safety and Pharmacodynamic Study of RV001, an Insulin-Like Growth Factor-1 Receptor (IGF-1R) Antagonist, Administered by Intravenous Infusion in Patients with Diabetic Macular Edema. Site principal Investigator 2015-2016.

Allergan Protocol 190342-038 BEACON: A Phase 2 Study Assessing the Safety and Efficacy of Brimonidine Intravitreal Implant in Geographic Atrophy Secondary to Age-Related Macular Degeneration. Site Principal Investigator 2015-2018.

Allergan Protocol 150998-005 CEDAR: A Phase 3 Study Assessing the Safety and Efficacy of Abicipar Pegol in Patients with Age-Related Macular Degeneration. Site Principal Investigator 2015-2019.

Alcon Protocol RTH-258-C001 HAWK: A Double-Masked, Multicenter, Three-Arm Phase 3 Study Comparing the Efficacy of RTH-258 Versus Aflibercept in Subjects with Neovascular Age-Related Macular Degeneration. Site Principal Investigator 2015-2019.

Genentech-Roche Protocol GX29176 CHROMA: A Phase 3, Multicenter, Randomized, Double-Masked, Sham-Controlled Study to Assess the Efficacy and Safety of Lampalizumab Administered Intravitreally to Patients with Geographic Atrophy Secondary to Age-Related Macular Degeneration. Site Principal Investigator 2016-2018.

Alimera Protocol M-01-15-004 PALADIN: A Phase 4 Safety Study of IOP Signals in Patients Treated with ILUVEIN (Fluocinolone Acetonide Intravitreal Implant). Site Principal Investigator 2016-2018.

Genentech-Roche Protocol BP29647 AVENUE: A Proof-of-Concept Study of RG7716 in Participants with Choroidal Neovascularization Secondary to Age-Related Macular Degeneration. Site Principal Investigator 2015-2017.

Genentech-Roche Protocol BP30099 BOULEVARD: A Phase 2 Study of RO6867461 in Participants with Center-Involving Diabetic Macular Edema. Site Principal Investigator 2016-2018.

Allergan Protocol 150998-006 SEQUOIA: A Phase 3 Study Assessing the Safety and Efficacy of Abicipar Pegol in Patients with Age-Related Macular Degeneration. Site Sub-Investigator 2016-2019.

Genentech Protocol GX28228 LADDER: A Phase 2 Study of the Efficacy and Safety of the Ranibizumab Port Delivery System for Sustained Delivery of Ranibizumab in Patient with Subfoveal Age-Related Macular Degeneration. Site Principal Investigator 2016-2019.

Genentech Protocol GX30191 OMASPECT: Long-Term Safety of Lampalizumab Intravitreal (ITV) Injections in Participants with Geographic Atrophy Secondary to Age-Related Macular Degeneration. Site Principal Investigator 2016-2018.

Genentech-Roche Protocol CR39521 STAIRWAY: A Phase 2 Study of Simultaneous Blockade of Angiopoietin-2 and VEGF-A with the Bispecfic Antibody RO6867461(RG7716) for Extended Durability in the Treatment of Neovascular Age-Related Macular Degeneration. Site Principal Investigator 2016-2019.

Clearside CLS1003-301 SAPPHIRE: A Phase 2 Study of Suprachoroidal Injection of Triamcinolone Acetonide with IVT Aflibercept in Subjects with Macular Edema Following RVO. Site Co-Principal Investigator 2017-2019.

Clearside CLS-1003-302 TOPAZ: A Randomized, Masked, Controlled Trial to Study the Safety and Efficacy of Suprachoroidal CLS-TA in Combination with Intravitreal an Intravitreal Anti-VEGF Agent in Subjects with Retinal Vein Occlusion. Site Principal Investigator 2018-2018.

Opthea OPT-302-1002: A Dose-Ranging Study of Intravitreal OPT-302 in Combination with Ranibizumab, Compared with Ranibizumab alone, in Participants with Neovascular Age-Related Macular Degeneration. Site Principal Investigator 2017-2019.

Opthea OPT-302-1003: Phase 1b/2a Study Of OPT-302 in Combination with Aflibercept for Persistent Central-Involved Diabetic Macular Edema. Site Principal Investigator 2018-2019.

Allergan MAPLE: Evaluation of Abicipar Pegol in Patient with Neovascular Age-related Macular Degeneration. Site Principal Investigator 2018-2019.

Genentech GR40549 PORTAL: A Multicenter, Open-Label Extension Study to Evaluate the Long-Term Safety and Tolerability of the Port Delivery System with Ranibizumab in Patient with Neovascular Age-Related Macular Degeneration. Site Principal Investigator 2018-Present.

Genentech GR40548 ARCHWAY: A Phase III, Multicenter, Randomized, Visual Assessor Masked, Active-Comparator Study of the Efficacy, Safety, and Pharmacokinetics of the Port Delivery System with Ranibizumab in Patients with Neovascular Age-Related Macular Degeneration. Site Principal Investigator 2018-2020.

Genentech GR40398 RHINE: A Phase III, Multicenter, Randomized, Double-Masked, Active, Comparator-Controlled Study to Evaluate the Efficacy and Safety of RO6867461 in Patients with Diabetic Macular Edema. Site Principal Investigator 2018-2022.

Chengdu KHB-1801 PANDA: A Multicenter, Double-Masked, Randomized, Dose-Ranging Trial to Evaluate the Efficacy and Safety of Conbercept Intravitreal Injection in Subjects with Neovascular Age-related Macular Degeneration. Site Principal Investigator 2018-2021.

Mylan MYL-1701P-3001 INSIGHT: A Multi Center, Randomized, Double-Masked, Active-Controlled, Comparative Clinical Study to Evaluate the Efficacy and Safety of MYL-1701P and Eylea in Subjects with Diabetic Macular Edema. Site Principal Investigator 2018-2021.

Genentech GR40306 TENAYA: A Phase III, Multicenter, Randomized, Double-Masked, Active Comparator-Controlled Study to Evaluate the Efficacy and Safety of Faricimab in Patients with Neovascular Age-Related Macular Degeneration. Site Principal Investigator 2019-2022.

Santen 010906IN LUMINA: A Phase III, Multicenter, Sham-Controlled, Randomized, Double-Masked Study Assessing the Efficacy and Safety of Intravitreal Injections of 440 μg DE-109 for the Treatment of Active, Non-Infectious Uveitis of the Posterior Segment of the Eye. Site Principal Investigator 2019-2022.

Kodiak KSI-CL-101: A Phase 1/1b Open Label, Multi-Center Exploratory Study to Investigate the Bioactivity, Ocular and Systemic Safety, Tolerability, and Pharmacokinetics following Single and Multiple Intravitreal Administrations of KSI-301 in Subjects with Wet Age Related Macular Degeneration, Diabetic Macular Edema, and Retinal Vein Occlusion. Site Principal Investigator 2019-2022.

Ionis 696844-CS5 GOLDEN: A Phase 2, Randomized, Placebo-Controlled, Double-Masked Study to Assess Safety and Efficacy of Multiple Doses of IONIS-FB-LRX, an Antisense Inhibitor of Complement Factor B, in Patients with Geographic Atrophy Secondary to Age-Related Macular Degeneration, Site Principal Investigator 2019-Present.

Genentech GR40973 GALLEGO: A Phase II, Multicenter, Randomized, Single-Masked, Sham−Controlled Study to Assess Safety, Tolerability, and Efficacy of Intravitreal Injections of FHTR2163 in Patients with Geographic Atrophy Secondary to Age-Related Macular Degeneration. Site Principal Investigator 2019-2023.

Genentech BP40899 DOVETAIL: A Multi-Center, Non-Randomized, Open-Label, Multiple Ascending Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of RO7200220 in Monotherapy and in Combination with Ranibizumab following Intravitreal Administration in Patients with Diabetic Macular Edema. Site Principal Investigator 2019-Present.

NGM621 Clinical Study Protocol 18-0501: A Phase 1, Multicenter, Open-Label, Single-Dose and Multiple-Dose Escalation Study of the Safety, Tolerability, and Pharmacokinetics of Intravitreal Injections of NGM621 in Patients with Geographic Atrophy Secondary to Age-Related Macular Degeneration. Site Principal Investigator 2018-2020.

Novartis CRTH258C2305 KINGFISHER: A 12-Month, 2-Arm, Randomized, Double-Masked, Multicenter Phase III Study Assessing the Efficacy and Safety of Brolucizumab every 4 weeks versus Aflibercept every 4 weeks in Adult Patients with Visual Impairment due to Diabetic Macular Edema. Site Principal Investigator 2019-2021.

Novartis CRTH258C2302 RAVEN: An Eighteen-Month, Two-Arm, Randomized, Double-Masked, Multi-center, Phase III Study Assessing the Efficacy and Safety of Brolucizumab versus Aflibercept in Adult Patients with Visual Impairment due to Macular Edema secondary to Branch Retinal Vein Occlusion. Site Principal Investigator 2019-2021.

Novartis CRTH258C2301 RAPTOR: An Eighteen-Month, Two-Arm, Randomized, Double-Masked, Multi-center, Phase III Study Assessing the Efficacy and Safety of Brolucizumab versus Aflibercept in Adult Patients with Visual Impairment due to Macular Edema secondary to Branch Retinal Vein Occlusion. SIte Principal Investigator 2019-2021.

Gyroscope Therapeutics GTSCOPE: A Study of Disease Progression in Genetically Defined Subjects with Geographic Atrophy Secondary to Age-Related Macular Degeneration. Site Principal Investigator 2019-Present.

Genentech GR40550 PAGODA: A Phase III, Multicenter, Randomized, Visual Assessor-Masked, Active Comparator Study of the Efficacy, Safety, and Pharmacokinetics of the Port Delivery System with Ranibizumab in Patients with Diabetic Macular Edema. Site Principal Investigator 2019-Present.

Novartis CRTH258AUS04 MERLIN: A Multicenter, Randomized, Double-Masked, Phase IIIa Study to Assess Safety and Efficacy of Brolucizumab Compared to Aflibercept in Patients with Neovascular Age-Related Macular Degeneration with Persistent Retinal Fluid. Site Principal Investigator 2018-2021.

Kodiak KSI-CL-102 DAZZLE: A Phase 2, Prospective, Randomized, Double-masked, Active Comparator Controlled, Multi-center Study to Investigate the Efficacy and Safety of Repeated Intravitreal Administration of KSI-301 in Subjects with Neovascular (Wet) Age-related Macular Degeneration. Site Principal Investigator 2019-2022.

Alkahest ALK4290-205: A Double-Masked, Placebo-Controlled, Dose Ranging Study to Evaluate the Efficacy of Oral AKST4290 with Loading Doses of Aflibercept in Patients with Newly Diagnosed Neovascular Age-Related Macular Degeneration. Site Principal Investigator 2020-2022.

Genentech BP41321 CANBERRA: A Randomized, Double-Masked 48-Week, Parallel-Group, Placebo-Controlled, Proof-of-Concept Study to Investigate the Efficacy and Safety of RG7774 in Patients with Diabetes Mellitus Type 1 or Type 2 with Treatment-naïve Diabetic Retinopathy. Site Principal Investigator 2020-Present.

Gyroscope GT005-02 EXPLORE: A Phase 2, Outcomes Assessor-Masked, Multicentre, Randomised Study to Evaluate the Safety and Efficacy of Two Doses of GT005 Administered as a Single Subretinal Injection in Subjects With Geographic Atrophy Secondary to Age-Related Macular Degeneration. Site Principal Investigator 2020-Present.

Bayer 20968 PULSAR: A Randomized, Double-Masked, Active-Controlled, Phase 3 Study of the Efficacy and Safety of High Dose Aflibercept in Patients with Neovascular Age-Related Macular Degeneration. Site Principal Investigator 2020-Present.

IVERIC Bio ISEE2008 GATHER2: A Phase 3 Multicenter, Randomized, Double-Masked, Sham-Controlled Clinical Trial to Assess the Safety and Efficacy of Intravitreal Administration of Zimura™ (Complement C5 Inhibitor) in Patients with Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration. Site Principal Investigator 2020-Present.

NGM NGM621-GA-201 CATALINA: A Phase 2 Multicenter, Randomized, Double-Masked, Sham-Controlled Study of the Safety and Efficacy of Intravitreal Injections of NGM621 in Subjects with Geographic Atrophy (GA) Secondary to Age-Related Macular. Site Principal Investigator 2020-2022

Gemini GEM-CL-10302: A Multicenter, Open-label, Multiple Dose Study in Patients with Geographic Atrophy Secondary to Dry Age-related Macular Degeneration to Evaluate the Safety, Tolerability, Pharmacodynamics, and Immunogenicity of Repeat Intravitreal Injections of GEM103. Site Principal Investigator 2020-2022.

Ocular Therapeutix DETeR: Investigator Initiated Study of the Effect on Pain and Inflammation with DEXTENZA Treatment in Patients Undergoing Routine Intravitreal Anti-VEGF Injections. Site Principal Investigator 2020-2022.

Genentech-Roche GR41987 RHONE-X: A Multicenter, Open-Label Extension Study to Evaluate the Long-Term Safety and Tolerability of Faricimab in Patients with Diabetic Macular Edema. Site Principal Investigator 2020-Present

Regeneron VGFTe-HD-DME-1934 PHOTON: A Randomized, Double-Masked, Active-Controlled Phase 2/3 Study of the Efficacy and Safety of High-Dose Aflibercept in Patients with Diabetic Macular Edema. Site Principal Investigator 2020-Present.

Genentech-Roche BP41670: A Two-Part, Phase I Study to Investigate the Safety, Tolerability, and Pharmacokinetics of RO7250284 following Intravitreal Administration of Unmasked Multiple Ascending Doses and Masked Sustained Delivery from the Port Delivery System in Patients with Neovascular Age-Related Macular Degeneration. Site Principal Investigator 2020-Present.

AsclepiX AXT107-CS101 CONGO: A Phase 1/2a Study of the Safety and Bioactivity of AXT107 in Subjects with Diabetic Macular Edema. Site Principal Investigator 2020-2022.

AsclepiX AXT107-CS102 SHASTA: A Phase 1/2a Study of the Safety and Bioactivity of AXT107 in Subjects with Neovascular Age-Related Macular Degeneration. Site Principal Investigator 2020-2022.

AsclepiX AXT 107-CS103 JASPER: A Phase 1/2a Study of the Safety and Bioactivity of AXT107 in Subjects with with Macular Edema due to Retinal Vein Occlusion. Site Principal Investigator 2020-2022.

Genentech-Roche GR42558 GALLAGOLE: A Multicenter, Open-Label Extension Study to Evaluate the Long-Term Safety and Tolerability of Intravitreal Injections of FHTR2163 in Patients with Geographic Atrophy Secondary to Age-Related Macular Degeneration. Site Principal Investigator 2021-2022.

Opthea OPT-302-1005 COAST: A Phase 3, Multicentre, Double-masked, Randomised Study to Evaluate the Efficacy and Safety of Intravitreal OPT-302 in Combination with Aflibercept, Compared with Aflibercept Alone, in Participants with Neovascular Age-related Macular Degeneration (nAMD). Site Principal Investigator 2021-Present.

COOL-3: A Randomized, Mased, Controlled Trial Studying the Use of Rapid Cooling Anesthesia as Local Anesthesia for Patients Receiving Intravitreal Injection. Site Principal Investigator 2021-2022.

Kodiak KS301P107 DAYLIGHT: A Prospective, Randomized, Double-masked, Active Comparator-controlled, Multi-center, Two-arm, Phase 3 Study to Evaluate the Efficacy and Safety of Intravitreal KSI-301 Compared with Intravitreal Aflibercept in Participants with Neovascular (Wet) Age-related Macular Degeneration (wAMD). Site Principal Investigator 2021-Present.

Kodiak KS301P107 GLIMMER: A Prospective, Randomized, Double-masked, Active Comparator-controlled, Multi-center, Two-arm, Phase 3 Study to Evaluate the Efficacy and Safety of Intravitreal KSI-301 Compared with Intravitreal Aflibercept in Participants with Visual Impairment Secondary to Treatment-naïve Diabetic Macular Edema (DME). Site Principal Investigator 2021-Present.

Gyroscope GT005-03 HORIZON: A Phase II, Open-Label, Outcomes-Assessor Masked, Multicentre, Randomised, Controlled Study to Evaluate the Safety and Efficacy of Two Doses of GT005 Administered as a Single Subretinal Injections in Subjects with Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration. Site Principal Investigator 2021-Present.

Genentech-Roche GR42691 AVONELLE-X: A Multicenter, Open-Label Extension Study to Evaluate the Long-Term Safety and Tolerability of Faricimab in Patients with Neovascular Age-Related Macular Degeneration. Site Principal Investigator 2021-Present.

Genentech-Roche GR41986 COMINO: A Phase III, Multicenter, Randomized, Double-Masked Active Comparator Controlled Study to Evaluate the Efficacy and Safety of Faricimab in Patients with Macular Edema Secondary to Central Retinal or Hemiretinal Vein Occlusion. Site Principal Investigator 2021-Present.

Genentech-Roche GR41984 BALATON: A Phase III, Multicenter, Randomized, Double-Masked, Active Comparator Controlled Study to Evaluate the Efficacy and Safety of Faricimab in Patients with Macular Edema Secondary to Branch Retinal Vein Occlusion. Site Principal Investigator 2021-Present.

Eyepoint EYP1901-001: A Phase 1, Multicenter, Prospective, Open-Label, Dose Escalation Study of EYP-1901, a Tyrosine Kinase Inhibitor (TKI), in Subjects with Wet AMD. Site Principal Investigator 2021-2022.
Annexon ANX007-GA-01 ARCHER: A Phase 2, Multicenter, Randomized, Parallel-Group, Double-Masked, 4-Arm, Sham-Controlled Study of the Efficacy, Safety, and Tolerability of ANX007 Administered by Intravitreal Injection in Patients with Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (AMD). Site Principal Investigator 2021-Present.

Genentech ML43000 BELVEDEREL: A Phase IV, Multicenter, Open-Label, Single arm Study of the Response to Treatment after Transition to the Port Delivery System with Ranibizumab (Susvimo [Ranibizumab Injection]) in Patients with Neovascular Age-Related Macular Degeneration Previously Treated with Intravitreal Agents other than Ranibizumab. Site Principal Investigator 2021-Present

Unity UBX1325-03: A Phase 2, Prospective, Multicenter, Randomized, Double-Masked, Active-Controlled Study to Assess the Safety, Tolerability, and Evidence of Activity of a Repeat Intravitreal Injection of UBX1325 in Patients with Neovascular Age-Related Macular Degeneration. Site Principal Investigator 2022-Present

Gyroscope GT005-01 FOCUS: An Open Label First in Human Phase I/II Multicentre Study to Evaluate the Safety, Dose Response, and Efficacy of GT005 Administered as a Single Subretinal Injection in Subjects with Macular Atrophy Due to Age-Related Macular Degeneration. Site Principal Investigator 2022-Present

Ocular Therapeutix OTX-TKI-2020-01: A Prospective Multicenter, Double-Masked, Randomized, Parallel-Group Study to Evaluate the Safety, Tolerability, and Efficacy of OTX-TKI (Axitinib Implant) for Intravireal Use in Subjects with Neovascular Age-Related Macular. Site Principal Investigator Degeneration 2022-Present

Regenxbio RGX-314-2103 ATMOSPHERE: A Phase 2, Open-label Study to Explore the Pharmacodynamics of Two Doses in Two Formulations of RGX-314 Gene Therapy Administered via Subretinal Delivery in Patients with Neovascular Age-Related Macular Degeneration. Site Principal Investigator 2022-Present

Regenxbio RGX-314-2104 ATMOSPHERE: A Randomized, Partially Masked, Controlled, Phase 2b/3 Clinical Study to Evaluate the Efficacy and Safety of RGX-314 Gene Therapy in Participants with nAMD. Site Principal Investigator 2022-Present

4DMT 4D-150-C001: A Phase 1/2 Dose-Escalation and Randomized, Controlled, Masked Expansion Trial of Intravitreal 4D-150 Gene Therapy in Adults with Neovascular (Wet) Age-Related Macular Degeneration. Site Principal Investigator 2022-Present

Genentech BP43445 ALLUVIUM: A Phase II, Multicenter, Randomized, Double Masked, Active Comparator controlled Study to Investigate the Efficacy, Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO7200220 Administered Intravitreally in Patients with Diabetic Macular Edema. Site Principal Investigator 2022-Present

Alexion ALXN2040-201: A Phase 2, Double-Masked, Placebo-Controlled, Dose Range Finding Study of Danicopan (ALXN2040) in Patients with Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (AMD). Site Principal Investigator 2022-Present

Eyepoint EYP-1901-201 DAVIO 2: A Phase 2, Multicenter, Prospective, Randomized, Double-Masked, Parallel Study ofEYP-1901, a Tyrosine Kinase Inhibitor (TKI), Compared to Aflibercept in Subjects with Wet AMD. Site Principal Investigator 2022-Present

Ocuterra OTT-166-201 DREAM: A Phase 2 Randomized, Double-Masked, Vehicle-Controlled, Multicenter Study to Evaluate the Safety and Efficacy of OTT 166 Ophthalmic Solution in the Treatment of Diabetic Retinopathy (DR). Site Principal Investigator 2022-Present

Novartis CLNP023E12201: A randomized, participant and investigator masked, placebo-controlled, multicenter, proof-of-concept study to assess the safety and efficacy of LNP023 (lptacopan) in patients with early and intermediate age-related macular degeneration. Site Principal Investigator 2022-Present

Allegenesis P2-73305-01: A multicenter, open-l;abeled, Phase 2A Study Evaluating the Safety, Tolerability, and Efficacy of Intravitreal AG-73305 in Patients with Diabetic Macular Edema. Site Principal Investigator 2022-Present

Genentech BP43464 BARDENAS: A Phase II, Multicenter, Randomized, Double Masked, Active Comparator-Controlled Study to Investigate the Efficacy, Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO7200220 Administered intravitreally in Patients with Diabetic Macular Edema. Site Sub-Investigator 2022-Present

Gyroscope GT-ORACLE: A Long-Term Follow-Up Study to Evaluate the Safety and Durability of GT005 in Participants with Geographic Atrophy Secondary to Age-Related Macular Degeneration Treated in a Gyroscope-Sponsored Antecedent Study. Site Principal Investigator 2022-Present

Regenxbio RGX-314-3101 ASCENT: A Randomized, Partially Masked, Controlled, Phase 3 Clinical Study to Evaluate the Efficacy and Safety of RGX-314 Gene Therapy in Participants with nAMD. Site Principal Investigator 2023-Present

Aviceda AVD-104-C01 SIGLEC: A Single and Multiple Dose Study to Evaluate the Safety, Pharmacokinetics, and Treatment Effect of Intravitreal AVD-104 in Participants with Geographic Atrophy Secondary to Age-related Macular Degeneration. Site Principal Investigator 2023-Present

Market Access Steering Committee, Regeneron, 2017-Present
US National Executive Committee for Faricimab, Genentech, 2018-Present
Ozanimod Multiple Sclerosis/Irritable Bowel Disease Macular Edema Review Panel Steve Gross, Tariq Bhatti, Andrew Lee 2018-Present
IVERIC Bio GA Next Generation Steering Committee, 2020-Present
Revive Biotechnology Scientific Advisory Board 2022-Present

Eichenbaum D, Goldstein B. Development of a novel intraocular foreign body basket, and design of prototype instruments. 2003-2005.

Eichenbaum D. Idiopathic Polypoidal Choroidal Vasculopathy (IPCV). Opencourseware. New England Eye Center, Tufts University School of Medicine, 2006. Accessed 27 March 2017. http://ocw.tufts.edu/data/37/496646.pdf

Retina World Congress Video Reviewer, 2022-Present

Partner for Community Eyecare with Lions Club of Tampa Bay, providing pro bono care to diabetics from the Clearwater Free Clinic, 2019-2021

ASRS Annual Meeting Abstract Reviewer, 2018-Present

Honorary Medical Chair, Foundation Fighting Blindness Vision Walk Tampa Bay, 2013

Associate Editor, British Medical Journal Ophthalmology, 2013-Present

Radio Reading Service for the Visually Impaired – WUSF 89.7 FM Tampa, Florida, 2003-2005

• Retina Society

• American Academy of Ophthalmology

• Association of Research in Vision and Ophthalmology

• American Society of Retina Specialists

• Vit-Buckle Society

• Club Vit

• Florida Society of Ophthalmology

• Tampa Bay Ophthalmic Society